ProCE Banner Activity

Daratumumab, Carfilzomib, and Dexamethasone in Lenalidomide-Refractory Relapsed Myeloma (MMY1001 Subgroup Analysis)

Slideset Download
Conference Coverage
Daratumumab with carfilzomib and dexamethasone was well tolerated and active in patients with lenalidomide-refractory relapsed multiple myeloma.

Released: June 03, 2018

Expiration: June 02, 2019

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Amgen, Inc.

Astellas Text

AstraZeneca

Celgene

Eisai

Genentech TEXT Only

Janssen

Merck Oncology

Seagen